Venturi Wealth Management LLC Purchases 46 Shares of Cencora, Inc. (NYSE:COR)

Venturi Wealth Management LLC boosted its position in shares of Cencora, Inc. (NYSE:COR) by 1.0% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,447 shares of the company’s stock after buying an additional 46 shares during the quarter. Venturi Wealth Management LLC’s holdings in Cencora were worth $1,001,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in COR. Oppenheimer & Co. Inc. bought a new position in Cencora during the 1st quarter valued at approximately $1,566,000. Atomi Financial Group Inc. purchased a new position in Cencora during the 1st quarter valued at $270,000. NorthRock Partners LLC bought a new position in Cencora in the 1st quarter worth $205,000. Meeder Advisory Services Inc. purchased a new stake in shares of Cencora in the 1st quarter worth about $675,000. Finally, Williams Jones Wealth Management LLC. bought a new stake in shares of Cencora during the 1st quarter valued at about $212,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Stock Up 0.3 %

Cencora stock opened at $249.09 on Tuesday. Cencora, Inc. has a one year low of $191.11 and a one year high of $251.52. The stock has a fifty day moving average of $231.95 and a 200 day moving average of $230.74. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.55 and a current ratio of 0.88. The stock has a market cap of $49.08 billion, a PE ratio of 33.17, a price-to-earnings-growth ratio of 1.61 and a beta of 0.44.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be given a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.88%. This is a positive change from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio is presently 27.16%.

Analysts Set New Price Targets

COR has been the subject of several research analyst reports. StockNews.com lowered shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. UBS Group boosted their target price on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Bank of America reiterated a “neutral” rating and set a $245.00 price objective (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Wells Fargo & Company upped their price target on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 1st. Finally, Leerink Partners dropped their target price on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and an average target price of $271.20.

Insider Transactions at Cencora

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the sale, the chairman now directly owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 15.80% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.